Rituximab (anti-CD20 monoclonal antibody) in lymphoproliferative malignancies: Tata Memorial experience. [electronic resource]
Producer: 20060605Description: 29-33 p. digitalISSN:- 0004-5772
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Murine-Derived
- Antigens, CD20 -- drug effects
- Antineoplastic Agents -- adverse effects
- Disease Progression
- Female
- Humans
- India
- Lymphoma, Non-Hodgkin -- drug therapy
- Male
- Middle Aged
- Proto-Oncogene Proteins c-bcl-2 -- drug effects
- Retrospective Studies
- Rituximab
- Survival Rate
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.